Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Jumps First Consent Decree Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.

You may also be interested in...



Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs

Sanofi-Aventis SA's drawn out and much-publicized semi-battle to acquire Genzyme Corp. for $20.1 billion, or $74 per share, plus potential future payments, ended on Feb. 16, in a deal that most of those involved as well as many onlookers said was an expensive, albeit strategic, win-win.

Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs

Sanofi-Aventis SA's drawn out and much-publicized semi-battle to acquire Genzyme Corp. for $20.1 billion, or $74 per share, plus potential future payments, ended on Feb. 16, in a deal that most of those involved as well as many onlookers said was an expensive, albeit strategic, win-win.

Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan

If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel